SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

ANALYST UPGRADES ZYNERBA, ENCOURAGED BY PROSPECTS FOR FRAGILE

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 2,878
Posts 207,845
Boards Moderated 1
Alias Born 07/30/07
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 8:01:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:09:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:08:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:07:22 PM
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/28/2017 7:02:33 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile... "GlobeNewswire Inc." - 9/28/2017 6:30:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:02:12 PM
Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences "GlobeNewswire Inc." - 9/6/2017 7:30:00 AM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing "InvestorsHub NewsWire" - 8/30/2017 10:29:33 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 "InvestorsHub NewsWire" - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code "InvestorsHub NewsWire" - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference "InvestorsHub NewsWire" - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market "InvestorsHub NewsWire" - 8/22/2017 1:27:13 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/14/2017 7:03:20 AM
Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthri... "GlobeNewswire Inc." - 8/14/2017 6:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 7:01:10 AM
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal ... "GlobeNewswire Inc." - 8/7/2017 6:45:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/1/2017 4:19:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/1/2017 7:31:42 AM
Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights "GlobeNewswire Inc." - 8/1/2017 7:30:00 AM
cjstocksup Member Level  Tuesday, 10/03/17 12:46:58 AM
Re: stocky101 post# 899
Post # of 965 
ANALYST UPGRADES ZYNERBA, ENCOURAGED BY PROSPECTS FOR FRAGILE X PHASE 2 STUDY

1:42PM ET 10/2/17


Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) investors may have reason for cautious optimism after the company's recent Fragile X Syndrome treatment data. On Monday, Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba to Overweight and said there is a reasonable change ZYN002 will find commercial success as a treatment for Fragile X. According to Piros, Cantor Fitzgerald sees a 30 percent probability of ZYN002 making it to the Fragile X market (see his track record here). However, even with less than a one in three chance of success, the Fragile X data has created some major value potential in Zynerba stock. Related Link: Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain "Based on the positive Phase 2 FXS results, we are encouraged by the potential for ZYN002 to treat the disease and have assessed the risk-adjusted opportunity for the drug," Elemer said. "With an annual price assumption of $45,000 (U.S.) and $32,000 (EU), ZYN002 could reach combined peak sales of $1.5 billion, in our calculation." For now, the firm is waiting for additional data and information from the company related to potential fundraising. Elemer expects Zynerba will secure additional financing within the next one to two years and will begin a phase II/III study in early 2018. Cantor Fitzgerald estimates Zynerba will finish 2018 with roughly $73 million in cash on its balance sheet. Elemer said ZYN002's potential Fragile X indication adds roughly $13 per share of risk-adjusted value to Zyberba. Cantor Fitzgerald has raised its price target for the stock accordingly, from $4 to $17. Zynerba's stock initially jumped 52 percent last week on the news but remain down more than 40 percent year to date. At time of publication, shares of Zynerba were up 3.91 percent at $8.69.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist